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A B S T R A C T
This study was performed to assess the effect of the S447X and Hind III lipoprotein lipase gene polymorphisms on de-
velopment of coronary artery disease and hypertriglyceridemia. The study included 132 patients and 98 healthy control
subjects of Croatian descent. The lipoprotein lipase S447X polymorphism was associated with coronary artery disease
and hypertriglyceridemia, as indicated by the lower frequency of S447 allele in the patient group (p=0.005) and odds ra-
tio (O.R=0.40, p=0.006). The patient and control groups also showed a significant difference in the distribution of Hind
III/S447X genotype combinations (p=0.013). There were no significant associations with lipid parameters for any geno-
type or genotype combination in the patient group. Frequencies of the S447X polymorphism and S447X/Hind III combi-
nations differed between the CAD/TG and control group, thus these polymorphisms may be associated with CAD and
hypertriglyceridemia.
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Introduction
Lipoprotein lipase (LPL) hydrolyzes the triacylgly-
cerol component of chylomicrons and very low-density
lipoproteins (VLDL), and indirectly participates in the
reverse transport of cholesterol1. Abnormal LPL expres-
sion takes part in some pathophysiological processes,
which include chylomicronemia, atherosclerosis, obesity,
diabetes, etc.2 It is also well known that hypertrigly-
ceridemia itself can be a risk factor for the development
of coronary artery disease (CAD), as well as of its lower-
ing effect on the levels of high-density lipoprotein choles-
terol (HDL-C)3. The genetic background in the interac-
tion with many other factors determines some changes of
the phenotype characteristics and influences some epide-
miological events4. Several common genetic variants in
LPL gene with different epidemiological effects have
been reported5–7. Summary statistics of multiple studies
have yielded statistically significant effects of some LPL
polymorphisms on the development of CAD. These in-
clude a twofold increase in CAD risk associated with the
lipoprotein lipase D9N and/or the –93T to G polymor-
phism, a marginal increase in CAD risk for N291S al-
lele-S carriers among individuals from six different stud-
ies, and association of S447X allele-X carriers with a de-
crease in CAD in four different studies7. Polymorphisms
affecting the noncoding region of LPL gene are also im-
plicated in the development of hypertriglyceridemia and/
or CAD. The most common and most widely investigated
are the Pvu II and Hind III polymorphisms6,8.
Over the last several years, many researchers have in-
vestigated allelic distribution of different LPL gene vari-
ants and their effect on lipid profiles in various patient
populations. In a previous study, we also investigated the
polymorphisms associated with CAD (–93T/G, D9N,
N291S and S447X)9. Recent studies have demonstrated
that LPL447X mutation was associated with higher
postheparin LPL activity in patients10. The S447X and
Hind III polymorphisms of the LPL gene represent two
variant sites that are within 600 bp of each other in the
gene11. It is also well known that these two polymor-
phisms are in the strong linkage disequilibrium11. Some
European studies showed a favorable effect of the 447X
allele on lipid traits, while some of them did not find any
significant influence on lipid parameters12. The EARS
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study showed that H-X447 haplotype was associated with
significantly lower concentrations of plasma triglycer-
ides (TG)11.
The aim of our study was to explore the possible ef-
fects of these two polymorphisms and their combinations
in CAD patients with elevated TG levels (CAD/TG group).
We therefore compared the frequencies of the S447X and
Hind III polymorphisms individually and the frequencies
of S447X/Hind III genotype combinations between the
CAD/TG and control groups. We have also investigated
the association between these two polymorphisms and
levels of plasma lipids.
Materials and Methods
Study subjects
Study subjects were recruited among patients who
underwent coronarography at Magdalena Specialized
Hospital for Cardiovascular Surgery and Cardiology in
Krapinske Toplice near Zagreb. The blood samples were
collected from 2001 to 2004. The subjects were divided
into two groups based on coronarography findings and
TG concentrations. The CAD/TG group included 132 pa-
tients with at least 50% stenosis of any of the major coro-
nary arteries and TG levels greater than 2.2 mmol/L (98
males, median age 59, range 34–82; and 34 females, me-
dian age 61.5, range 38–73). The control group included
98 subjects with 10% stenosis of major coronary arter-
ies, TG levels lower than 2.0 mmol/L, and without evi-
dence of any chronic disease (60 males, median age 52.5,
range 18–76; and 38 females, median age 61, range
26–76). Patients who had a family history of acute or
chronical pancreatitis were excluded from the study be-
cause of known relationships between changes in LPL
activities and pancreatitis6. We used WHO criteria to de-
fine diabetes in both study groups13. We have also ex-
cluded patients with extremely high lipid concentrations,
because they would complicate statistic analysis. Pa-
tients gave an informed consent to participate in the
study, which was approved by the Ethics Committee of
Magdalena Specialized Hospital for Cardiovascular Sur-
gery and Cardiology in Krapinske Toplice and of the
Zagreb University School of Medicine.
Determination of plasma lipid and lipoprotein
subclass concentrations
Blood samples were collected after an overnight fast.
The concentrations of total cholesterol (TC) and TG were
measured by standard enzymatic methods on an Olym-
pus AU-640 (Olympus, Tokyo, Japan). HDL-C was deter-
mined by selective precipitation (Immuno AG, Vienna,
Austria), and also measured on an Olympus AU-640.
Low density lipoprotein cholesterol (LDL-C) was calcu-
lated using Friedewald equation14. If TG concentration
was greater than 3.0 mmol/l, HDL-C was measured by di-
rect immunoinhibition method (Olympus Diagnostica
GmbH, Lismeehan, Ireland), and LDL-C by homogene-
ous assay (Randox Laboratories, Crumlin, United King-
dom). Apolipoproteins (apo) A–I and B were measured by
the nephelometric method (Dade Behring, Marburg, Ger-
many).
PCR amplification and RFLP analysis
DNA was extracted from peripheral whole blood by
the salting out method15. Polymerase chain reaction (PCR)
for exon 9 of LPL gene was performed using primers pre-
viously described by Monsalve et al16. The reactions were
performed in a DNA thermocycler (Eppendorf Master-
cycler 3350, Hamburg, Germany), as described elsewhe-
re17. S447X polymorphism was genotyped by digestion of
exon 9 with Hinf I restriction endonuclease (Roche,
Mannheim, Germany). Hind III locus was genotyped us-
ing Eppendorf Mastercycler 3350 and oligonucleotides,
PCR and restriction conditions as previously describ-
ed17,18.
Statistical analysis
Statistical analysis was performed by use of StatSoft,
Inc. (2003) STATISTICA (data analysis software system)
version 6.1, and MedCalc 4.10 (Frank Schoonjans, Mari-
akerke, Belgium). Genotype frequencies were calculated
by counting. Group comparisons of categorical variables
were performed using Pearson’s 2 or Fisher’s exact test.
Hardy-Weinberg equilibrium was tested by 2-test. Odds
ratios were calculated for assessment of association be-
tween LPL gene polymorphisms and CAD. All continuous
data were expressed as XSD. Differences between the
two groups studied were evaluated by Student’s t-test or
Mann-Whitney test, depending on distribution normal-
ity. Multivariate analysis (MANOVA) with age, gender
and diabetes as covariates were used for testing of the ef-
fects of LPL gene polymorphisms on lipid parameters. TG
values were not normally distributed and were therefore
log-transformed. The level of significance was set at 0.05.
Results
The characteristics and lipid parameters of the two
groups are presented in Table 1. There were more males,
diabetics and smokers in the CAD/TG group. HDL-C was
significantly lower and LDL-C higher in the CAD/TG
group.
Table 2 shows genotype frequencies in the two study
groups. The observed genotypes were in Hardy-Weinberg
equilibrium for all the genetic variants examined. Car-
riers of the 447X allele were more frequent in the control
group, while there was no significant differences be-
tween groups in genotype frequencies for the Hind III
polymorphism. The odds ratio for the association of
S447X polymorphism with CAD and hypertriglyceride-
mia (O.R.) was 0.40 (p=0.006). The frequencies of geno-
type combinations for the S447X and Hind III poly-
morphisms are also presented in Table 2. There are nine
possible combinations but only six of them were ob-
served. There was a statistically significant difference be-
tween the CAD/TG and control group in the distribution
of different Hind III/S447X genotype combinations. As
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hypertriglyceridemia can be a consequence of diabetes,
we examined the effect of excluding diabetic subjects.
Without diabetic subjects, the S447X genotype frequen-
cies, as well as the Hind III/S447X genotype combination
frequencies were still significantly different between the
CAD/TG and control groups.
To explore possible mechanisms for this protective ef-
fect, the associations between LPL genotypes and geno-
type combinations and some plasma lipid traits (TC, TG,
HDL-C, LDL-C, apo A–I and apo B) were examined in the
CAD/TG group. The results are presented in table 3. Due
to the low frequency of the H-H– genotype, the H-H– and
H-H+ genotypes were pooled together as a single sub-
group (H–&+) and compared with the subgroup consist-
ing of the H+H+ genotype. There was no significant ge-
notype effect on lipid parameters for any of the geno-
types or genotype combination.
Discussion
When investigating possible LPL genotype effects,
one has to take into account that the LPL enzyme can
have both pro- and anti-atherogenic roles1. The main role
of the LPL is its catalytic activity that includes hydroly-
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TABLE 1







Age, years (range) 59 (34–82) 56.5 (18–76)
Sex (male), n (%) 98 (74.2) 60 (61.2) 0.035
Hypertension, n (%) 68 (51.5) 51 (52.0) 0.937
Diabetes, n (%) 28 (21.2) 3 (3.1) <0.001
Smoking, n (%) 44 (33.3) 22 (22.4) 0.071
Glucose, mmol/L (XSD) 6.613.26 5.191.26 <0.001
TC, mmol/L (XSD) 6.11.6 5.331.05 0.414
TG, mmol/L (XSD) 3.090.85 1.240.35 Not doneb
HDL-C, mmol/L (XSD) 0.950.24 1.210.33 <0.001
LDL-C, mmol/L (XSD) 3.981.27 3.350.90 0.002
Apo A-I, g/L (XSD) 1.260.29 1.430.34 0.161
Apo B, g/L (XSD) 1.250.31 1.020.25 0.244
aDifferences between groups were evaluated by Student’s t-test or Mann-Whitney test, depending on distribution normality.
b TG values were used to define the CAD/TG group (TG >2.2 mmol/l) and control groups
TABLE 2
FREQUENCIES OF GENOTYPES AND GENOTYPES COMBINATIONS IN CAD/TG AND CONTROL GROUP
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a Comparison of study groups were performed by using Pearson’s 2 or Fisher’s* exact test.
sis of TGs from TG-rich lipoproteins. This main catalytic
activity is involved in antiatherogenic effects. Namely, di-
minishing TGs in blood can limit reduction of HDL-cho-
lesterol mediated by cholesteryl ester transfer protein19.
This leads to low HDL-C concentrations as reported in
hypertriglyceridemic humans1. We have also reported on
inverse correlations between concentrations of HDL-C
and TGs20. In contrast to the anti-atherogenic role, pro-
-atherogenic effects have also been well defined in some
animal models21. In the vessel wall, LPL activity may be
associated with lipoprotein retention because of foam cell
formation22. As a consequence of its transferase activity,
LPL possibly induces cholesteryl ester accretion in smo-
oth muscle cells during atherogenesis21. The anti-athe-
rogenic role is mostly due to plasma LPL, whereas the
pro-atherogenic role is mediated by LPL from vessel wall
epithelial cells and macrophages.
The present study investigated the S447X and Hind
III lipoprotein lipase polymorphisms and lipid profiles in
patients with CAD and TGs greater than 2.2 mmol/l rela-
tive to control subjects. These two different polymor-
phisms proved relevant and comparable with many simi-
lar studies. It is well known that lowering of LPL activity
can influence the development and progression of athe-
rosclerosis1. Diabetes mellitus may be secondary cause of
hypertriglyceridemia23, because individuals with impair-
ed glucose tolerance and with diabetes mellitus have a
slower plasma reduction of TGs24. Consequently, we have
calculated and analyzed the frequencies between the
CAD and the control group with and without diabetics to
exclude the influence of hyperglycemia. Many studies re-
port on a decrease in CAD risk in individuals carrying
447X-allele, in European and American populations, as
well as Japanese7,25. The frequency of the X447 gene
variant was also significantly lower in over than 1,300
myocardial infarction survivors than in the same num-
ber of the control subjects from the Central Valley of
Costa Rica26. We similarly observed a significantly lower
frequency of 447X-carriers among those with CAD.
Studies of in vitro expression showed both increased
or unchanged activity and mass of LPL-X447 relative to
S44712 and studies of in vivo activity yield inadequate
data for any general conclusion12. Many lipid association
studies indicated a lowering effect on TGs and/or higher
HDL-C concentrations in X447 carriers5, 27–31; therefore
this beneficial LPL 447-X gene variant was considered
for a gene therapy investigation32. Other recent studies,
which include English33 and Welsh34 populations, did not
indicate significant changes of TGs or HDL-C. These lat-
ter findings are in agreement with our study results. A
lower LPL-X447 allele frequency was found in the LPL
deficient cohort compared to Quebec population-based
cohort, suggesting that beneficial LPL-X447 allele in
combinations with some mutant alleles do not provide
protective effect against the risk to develop CAD35. The
HERITAGE family study showed that the relationships
between the X447 allele and beneficial lipid profile were
observed in obese but not in normal-weight subject36
probably due to a higher LPL activity in obese people.
The association of LPL gene mutations with CAD ap-
peared to be exacerbated by the presence of additional
risk factors, gene-gene, gene-environmental interactions
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TABLE 3




















H–&+ 6.381.18 3.10081 1.000.25 4.251.25 1.290.29 1.310.31
H+ 5.921.32 3.070.87 0.930.22 3.791.26 1.240.29 1.210.31
Significance, p 0.813 0.813 0.176 0.080 0.063 0.065
S447X
SS 6.051.30 3.090.84 0.960.23 3.921.23 1.270.29 1.250.31
SX 6.441.13 3.100.92 0.960.30 4.371.29 1.230.26 1.290.32
Significance, p 0.136 0.913 0.427 0.137 0.075 0.142
Genotype combinations
SS/– – 6.300.57 2.720.50 1.040.13 4.500.88 1.330.24 1.330.15
SS/–+ 6.361.32 3.190.78 1.020.24 4.141.30 1.330.31 1.320.34
SS/++ 5.921.32 3.080.87 0.930.22 3.791.26 1.240.29 1.210.31
SX/– – 6.450.64 3.201.03 1.140.20 4.651.06 1.400.11 0.940.25
SX/–+ 6.441.19 3.080.94 0.940.30 4.341.34 1.210.27 1.320.31
Significance, p 0.262 0.817 0.336 0.241 0.155 0.087
a Differences between groups were evaluated by multivariante analysis and TGs were log-transformed before testing.
bP-values were calculated after adjustment for age, sex and diabetes.
and lifestyle habits. Those facts, as well as inclusion cri-
teria in the design of our study, such as CAD+hyper-
triglyceridemia, may modify the effect of polymorphisms
on the lipid traits. Therefore we were unable to show ex-
pected benefits on lipid profiles such as lower TG concen-
trations.
The LPL Hind III polymorphism may affect RNA
splicing because lies in intron eight, 495 bp from the
splice-donor site6. It has been proposed that the H-allele
of the Hind III polymorphism acts as a genetic marker
for a functional mutation that could cause either en-
hanced enzyme activity or more efficient lipid binding11.
It is in strong linkage disequilibrium with S447X poly-
morphism11,12. Therefore S447X and Hind III LPL poly-
morphisms are candidates that might be involved to-
gether in the development of CAD and hypertriglyceridema.
We have also documented in this paper that almost all
Croatian subjects with the Hind III H+H+ genotype had
the 447SS genotype. This was comparable with the re-
sults from the European Atherosclerosis Research Study,
which included university students from 12 European
countries and investigated haplotype effects11. Although
Hind III genotypes alone did not differ in frequencies be-
tween our two subgroups studied, there was a statisti-
cally significant difference in gene combinations with
S447X. The H+H+/SS genotype combination was more
prevalent in CAD/TG than in the control group. Namely,
H+H+/SS genotype combination seems to be unfavor-
able and may be involved in the development of CAD.
The LPL-H+ and LPL S447 alleles have been associ-
ated with an increased risk for the development of CAD
or hyperlipoproteinemia in a number of other studies.
The H+H+ genotype was associated with predisposition
to myocardial infarction in Russian patients37 and the
Hind III polymorphism correlated significantly with
cerebrovascular disease in Japanese subjects38. Among
German patients included in the MONICA study there
was no difference in the frequencies of Hind III geno-
types between patients and controls, but there were ob-
served unfavorable lipid levels in homozygotes for H+
allele4. The H+ allele was also connected with some un-
favorable lipid profiles in Spanish and US-American
women39,40. By comparison, as in the study presented
here, there was no observed association between the
Hind III polymorphism and lipid profile among over-
weight, postmenopausal, US-American woman41 nor in
the Quebec family study29,42. Although we expected that
patients with CAD and high TGs might have unfavorable
lipid profile with LPL polymorphisms mentioned above,
we did not find any significant influence of these poly-
morphisms. Data from the literature suggests that this
effect may depend upon the specific patient population
studied.
In summary, the S447X polymorphism and genotype
combination of S447X and Hind III polymorphisms were
shown to differ in frequencies between CAD/TG and con-
trol groups, suggesting their association with CAD and
hypertriglyceridemia.
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POVEZANOST DVIJU VARIJANTI GENA ZA LIPOPROTEIN LIPAZU S KORONARNOM BOLESTI
SRCA I HIPERTRIGLICERIDEMIJOM
S A @ E T A K
Cilj ovog rada je bio ispitati u~inak polimorfizama S447X i Hind III u genu za lipoprotein lipazu na razvoj koronarne
bolesti srca i hipertrigliceridemiju. U istra`ivanje je uklju~eno 132 ispitanika s koronarnom bolesti srca i triacilgli-
cerolom iznad 2.2 mmol/L i 98 zdravih ispitanika iz Hrvatske. U grupi ispitanika s koronarnom bolesti srca i povi{enim
triacilglicerolom u~estalost S447 alela u genu za lipoprotein lipazu zna~ajno je manja nego li kod kontrolne skupine
(p=0.005) {to potvr|uje i statisti~ki zna~ajan omjer vjerojatnosti (O.R.=0.40, p=0.006). Tako|er je statisti~ki zna~ajna
razlika u~estalosti kombinacija gena Hind III/S447X izme|u ispitivanih skupina (p=0.013). Genotipovi kao ni kom-
binacije genotipova nisu se zna~ajno razlikovale u lipidnom profilu nijedne od ispitivanih skupina. Kako se u~estalost
S447X polimorfizma i kombinacije polimorfizama Hind III/S447X u genu za lipoprotein lipazu razlikuju izme|u paci-
jenata i kontrolnih ispitanika mo`e se zaklju~iti da su navedeni polimorfizmi mogu imati utjecaja na razvoj koronarne
bolesti srca i hipertrigliceridemije.
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